Gallium Ga 68-labeled GRPR Antagonist BAY86-7548

DRUG2 trials

Sponsors

Andrei Iagaru

Conditions

Breast CarcinomaEstrogen Receptor PositiveStage II Prostate AdenocarcinomaStage III Prostate AdenocarcinomaStage IV Prostate Adenocarcinoma

Phase 1

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

CompletedNCT03831711

Andrei IagaruBreast Carcinoma, Estrogen Receptor Positive

Start: 2019-03-19End: 2021-11-15Updated: 2023-12-13

Phase 2

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

CompletedNCT03113617

Andrei IagaruStage III Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma

Start: 2017-04-10End: 2021-12-19Updated: 2023-12-12

Related Papers

Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.

2023-08-097 citations